This fixed-dose combination is primarily used across therapeutic domains where acute symptomatic discomfort is characterized by the co-occurrence of musculoskeletal pain and involuntary muscle rigidity. This class of medication may be part of symptomatic management to help ease stiffness and tension. Rexivin is commonly applied in clinical settings for conditions marked by heightened symptoms, such as muscle strains, ligament sprains, and low back discomfort that involve swelling. Applicable in conditions marked by temporary functional strain, it helps address groups of symptoms that may appear suddenly, offering symptomatic relief that contributes to improved day-to-day comfort during periods of heightened tension.

“This medication is relevant for use in situations requiring short-term symptomatic assistance to manage pain and stiffness that interfere with daily functioning.”

By easing challenging symptoms, it offers supportive therapeutic benefit that helps patients cope more steadily with difficult episodes and may assist with maintaining functional stability during physical rehabilitation.

Quick Fact: Relief for Acute Musculoskeletal Stress
Primary Symptoms Eased: Pain, Inflammation, and Muscle Spasm
Use Context: Conditions characterized by acute, short-term muscular rigidity and discomfort
Core Benefit: Contributes to easing the overall symptom load during recovery

Regulatory References

1. NIH MedlinePlus Drug Information on Chlorzoxazone

This section outlines the officially documented population eligibility and non-eligibility for Rexivin (Diclofenac, Chlorzoxazone FDC), as defined by government regulatory agencies. The restrictions for this combination are based on the most stringent requirements for its two active ingredients.

---

Eligibility Scope

Category	Official Regulatory Status
Populations for whom use is allowed	Adults are the indicated population [Source 1.1].
Populations for whom use is not recommended	Older adults (use lowest effective dose) [Source 1.1]. Nursing mothers (use is generally not recommended) [Source 3.6]. Women between 20 and 30 weeks gestation (limit use) [Source 3.7].
Populations for whom use is contraindicated	Patients with known hypersensitivity to any component or history of NSAID-related allergy (e.g., aspirin-sensitive asthma) [Source 1.1]. Patients in the setting of CABG surgery [Source 2.5]. Patients with active GI ulceration or severe heart, hepatic, or renal failure [Source 1.7]. Patients with established ischaemic heart disease or congestive heart failure (NYHA Class II-IV) [Source 1.6].
Age-related eligibility rules	Use in the pediatric population is not established [Source 1.3].

---

Eligibility Classifications (High-Level)

Category	Official Regulatory Status
Eligibility severity classification	Contraindicated (highest severity exclusion for specific groups) [Source 1.1]. Avoid Use (strong restriction for severe organ impairment) [Source 2.5]. Not Established (for pediatric use) [Source 1.3].
Pregnancy and lactation eligibility status	Pregnancy (ge 30 weeks gestation): CONTRAINDICATED [Source 2.5]. Lactation: Not recommended [Source 3.6].

---

Resulting Eligibility Structure

Official eligibility statements:

• The medicine is contraindicated in the last trimester of pregnancy and in patients with specific established cardiovascular diseases or active gastrointestinal bleeding [Source 1.6, 2.5].
• Use in the pediatric population is not established due to a lack of safety and efficacy data [Source 1.3].
• Patients with severe organ failure (hepatic, renal, or cardiac) are ineligible for use [Source 1.7].
• Older adults require caution and the lowest effective dose due to an increased risk of serious adverse events [Source 1.1].

Connection to the overall eligibility profile:

Regulatory documents define who can and cannot use this drug by establishing absolute exclusions (contraindications) for groups with organ failure, active GI disease, specific CV risk factors, and late-stage pregnancy. Use is officially limited to adults and requires a cautious, restricted approach in the elderly and those with organ impairment, thereby structuring the non-advisory boundary for its approved use.

Interactions with other medicines and products

Official regulatory documents describe potential interactions for the fixed-dose combination product based on its active components, Diclofenac (an NSAID) and Chlorzoxazone (a muscle relaxant). These interactions generally require patient monitoring or caution during co-administration.

Pharmacodynamic and Pharmacokinetic Interactions

Active Component	Interacting Medicinal Product Categories	Mechanistic/Resulting Constraint
Diclofenac	Anticoagulants and Antiplatelet agents (e.g., Warfarin, SSRIs)	Increased risk of bleeding; requires monitoring.
	Diuretics (e.g., Thiazides) and Antihypertensives	Reduced efficacy of these agents; requires monitoring of blood pressure and renal function.
	Other NSAIDs (e.g., Aspirin)	Increased risk of serious gastrointestinal adverse events; combination is generally restricted.
	Lithium, Digoxin, Methotrexate, Cyclosporine	Increased plasma levels of these co-administered drugs.
Chlorzoxazone	Central Nervous System (CNS) Depressants, Alcohol	Additive CNS depressant effects, increasing sedation.

Interaction-Related Constraints

Official labeling requires monitoring of renal function in high-risk patients (e.g., those with volume depletion) due to the Diclofenac component's effects. The concurrent use of alcohol is linked to enhanced CNS depression, representing a cautionary constraint. Similarly, use with Quinolone antibiotics has been associated with a risk of precipitating convulsions. The combination of Diclofenac with other NSAIDs is strongly restricted due to the amplified risk of gastrointestinal complications, necessitating the careful selection of pain relief or anti-inflammatory therapies.

Rexivin is a fixed-dose combination product containing Diclofenac and Chlorzoxazone, which modulate physiological pathways via distinct mechanisms.

Diclofenac functions as a non-selective, reversible inhibitor of Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. This molecular interaction competitively prevents the conversion of the substrate arachidonic acid into prostaglandin H2 (PGH2). The resulting downstream cascade is a systemic reduction in the biosynthesis of pro-inflammatory and nociceptive prostanoids, including PGE2 and thromboxanes, which modulate inflammation and afferent nerve sensitization.

Chlorzoxazone is a centrally-acting agent. Its primary mechanism involves acting at the level of the spinal cord and subcortical areas of the brain. This interaction results in the inhibition of polysynaptic reflex arcs, which are neural pathways involved in maintaining skeletal muscle hyperactivity. This central modulation of efferent nerve firing decreases skeletal muscle motor output.

Administration Guidelines

This section outlines usage instructions for the Chlorzoxazone and Diclofenac fixed-dose combination (FDC) based on prescribing information which mandates label-based use.

Administration Scope	Requirement
Route of Administration	Oral (by mouth) tablet.
Standard Adult Dosing	One tablet per dose.
Frequency and Schedule	Two to three times daily, or as directed by a healthcare professional.
Duration Constraint	Use the lowest effective dosage for the shortest duration necessary to achieve treatment goals, consistent with NSAID labeling.

---

Procedural Instructions

The correct use of this medicine is defined by these specific steps:

• Ingestion: The tablet must be swallowed whole with a liquid.
• Preparation: No preparation, dilution, or reconstitution is required. Tablets should generally not be crushed or chewed (standard instruction for many FDC tablets containing NSAIDs).
• Timing: The medication may be taken with food or milk if stomach upset occurs. However, food generally does not have a significant effect on the extent of absorption for the Diclofenac component.
• Missed Dose: If a dose is missed, take it as soon as possible. If it is almost time for the next scheduled dose, skip the missed dose and resume the regular dosing schedule; do not double the dose.

Population-Specific Use

Elderly Patients: Caution is required. Elderly patients may require lower initial dosages due to increased sensitivity and potential age-related organ issues. Use should be approached cautiously due to the risk of side effects.

Research evidence / Overview of studies for Rexivin (Chlorzoxazone, Diclofenac FDC)

Evidence for Acute Musculoskeletal Pain Associated with Spasm

The combination approach was evaluated in research for its use, such as the one in Rexivin, in various clinical studies. The research examined this therapeutic principle in contexts relevant in trials assessing short-term or episodic symptom patterns. The studies exploring this approach were conducted as Randomized Controlled Trials (RCTs) or included in systematic reviews. The researchers primarily monitored outcomes related to physical discomfort, such as measurements of pain intensity, alongside studies also monitored outcomes related to muscle tension.

Studies focused on the principle of combining these medicine types examined outcomes related to physical discomfort and studied outcomes related to muscle tension over a defined observation period. Research highlights changes measured during the study period, particularly with outcomes describing episodic or acute changes. The research contributes to the broader evidence landscape regarding how patients reported their experience when symptoms were fluctuating or unstable. However, the evidence is limited to short-term changes, and some reports indicate that findings were mixed across studies involving similar combination principles.

Evidence for Acute Low Back Pain (LBP) with Muscle Rigidity

Research explored the use of this therapeutic approach in conditions associated with acute or disruptive episodes, such as acute low back pain. These studies examined outcomes monitoring physiological strain or stress and explored outcomes reflecting daily functioning or activity level. Studies focused on adults with conditions marked by functional limitations and periods of heightened symptoms.

Evidence from Short-Term Trials and Follow-Up Duration

The primary evidence is derived from research exploring short-term symptom changes, with studies conducted during periods of increased symptom activity. Follow-up durations were limited, typically spanning only a few days up to about one week, applied in research contexts involving fluctuating or unstable symptoms. The evidence contributes to the broader evidence landscape regarding symptom patterns and how symptoms evolved in the observed populations during these brief, defined time intervals. However, because of these modest follow-up durations, there is limited information for long-term outcomes, meaning that the extended measured effects and durability of response are not fully established.

Evidence in Specific Patient Populations

Evidence is limited in areas concerning the use of the medicine in specific populations, such as children (pediatric groups) and older adults (geriatric groups). There is limited information for outcomes related to systemic or functional imbalance in individuals with comorbid conditions that were excluded from the main trials. Data for certain groups remain insufficient outside the defined patient groups evaluated in the original trials.

Key Uncertainties and Research Gaps

Dedicated clinical trial data establishing the therapeutic basis for this precise FDC structure remains a focus for regulatory review, and comparative evidence is lacking. The evidence quality varies across studies, and findings were mixed when considering similar combination approaches, suggesting that data are still emerging. Research describes short-term changes but does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. Comparative Efficacy of Pharmacological Therapies for Low Back Pain: A Bayesian Network Analysis - Frontiers
2. F. No. 04-146/2007-DC - Government of India - Central Drugs Standard Control Organization (FDC Division) - Review of Fixed Dose Combinations
3. Label: CHLORZOXAZONE tablet - DailyMed - NIH (for painful musculoskeletal conditions)

Common questions about Rexivin (Chlorzoxazone, Diclofenac FDC) (FAQ)

Q: What does 'centrally acting' mean in relation to Chlorzoxazone?

According to official product information, the Chlorzoxazone component is described as a centrally-acting agent. It is defined as acting by affecting the central nervous system, specifically the spinal cord and subcortical areas of the brain. This action is understood to involve the inhibition of nerve pathways involved in maintaining muscle spasm.

---

Q: What are the restrictions on using Rexivin for pregnant or nursing women?

Regulatory documents state that use is generally not recommended for nursing women. For pregnant women, the medicine is contraindicated (should not be used) during the last trimester, which is at or after 30 weeks of gestation. Use is also generally discouraged between 20 and 30 weeks of gestation.

---

Q: What are the signs of a serious gastrointestinal issue I should watch out for?

The regulatory safety profile highlights the risk of serious gastrointestinal issues, such as bleeding or ulcers. Regulatory guidance suggests seeking immediate medical attention if signs such as vomiting blood, passing bloody or black stools, or having persistent, severe stomach pain are observed.

---

Q: Can I take Rexivin if I have heart disease or a history of stroke?

Official product information states that this medicine is contraindicated in patients with certain established cardiovascular conditions. These include severe heart failure, specific types of ischaemic heart disease, and following coronary artery bypass graft (CABG) surgery. The regulatory summary indicates that cardiovascular risks may also increase with the dose and duration of use.

---

Q: How quickly should I expect Rexivin to start working for my pain?

Pharmacokinetic studies indicate that the Chlorzoxazone component, which addresses muscle spasm, is rapidly absorbed after being taken orally. Peak blood levels for this muscle relaxant effect are typically reported to be reached within about 1 to 2 hours after administration.

---

Q: What should I do if my symptoms do not improve after taking Rexivin?

Official regulatory guidance suggests consulting a healthcare professional if symptoms do not improve. This guidance is relevant if pain or symptoms persist, worsen, or reoccur after the defined treatment period.

Official Storage and Disposal Requirements

Rexivin tablets must be stored at room temperature and kept in the original, tightly closed container to maintain stability. Regulatory instructions require the medication to be protected from both excess heat and moisture, and stored in a location that is shielded from light.

Mandatory Safety & Disposal

The product must always be kept out of the sight and reach of children and secured in a locked space to prevent accidental ingestion. When discarding unused or expired medicine, regulatory guidance advises against flushing it down the toilet. The preferred method is using a drug take-back program or utilizing the approved household trash disposal method to comply with environmental guidelines.